Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
Hiroji UemuraKazuki KobayashiAkira YokomizoShiro HinotsuShigeo HorieYoshiyuki KakehiNorio NonomuraOsamu OgawaMototsugu OyaKazuhiro SuzukiAtsushi SaitoKeiko AsakawaSatoshi UnoSeiji NaitoPublished in: International journal of clinical oncology (2022)
The results were similar in all subscales of each PRO, demonstrating similar HRQoL deterioration based on MID criteria between the enzalutamide and flutamide groups.
Keyphrases